2025 was a tough, dreary year for biotech, with a challenging IPO environment, reduced dealmaking, and many companies facing difficulties in reaching their revenue goals, alongside significant legislative changes. Some have described the biotech landscape as a flattish growth trend.
Still, cautious optimism was felt among those attending and presenting at the 2026 JP Morgan Conference, healthcare’s largest dealmaking event of the year, sparking hope for a positive reset in the year ahead.
A reset is great news for product developers and the patients they serve – more deals mean more treatment options. But how can biotechs, especially emerging and small to mid-sized, position themselves as attractive as possible to investors to propel their development forward?
We sat down with Joshwa Moon, VP, Head of Sales in North America at ProductLife Group, and Albert Ballester, Head of Corporate Development at ProductLife Group after returning from a busy week to hear feedback from the event, packaging it up into advice for biotechs.
Key message is this – while there is a positive sentiment echoed across the industry, there are still choppy waters ahead, and it is essential to pressure test operational and inspection-readiness.
Read their Q&A in the original article published on ProductLife Group.
Halloran Consulting Group is a ProductLifeGroup company.